The capital infusion validates Gate Bioscience’s novel protein‑targeting platform and accelerates its path to clinic, potentially reshaping drug discovery for inflammatory and neurological diseases. Participation by a major pharma player like Eli Lilly signals industry confidence and could spur further collaborations.
Comments
Want to join the conversation?
Loading comments...